Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Non Operating Income (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Non Operating Income for 9 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income changed N/A to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $11.5 million for FY2025, 2.92% down from the prior year.
  • Non Operating Income for Q4 2025 was $3.8 million at Soleno Therapeutics, down from $3.9 million in the prior quarter.
  • The five-year high for Non Operating Income was $3.9 million in Q3 2025, with the low at $1.8 million in Q2 2025.